Mithra Signs Principle Agreement for Commercialization of Estelle® in Canada with Women’s Health Specialist Searchlight Pharma

  • Mithra eligible for upfront milestones, recurring revenues and further sales-related payments, for a potential total deal value of at least EUR 50 million
  • With Estelle®, Searchlight aims to further expand its growing footprint in Women’s Health

Liège, Belgium, 12 April 2018 – Mithra (Euronext Brussels: MITRA), a company specialized in Women’s Health, today announced that it has signed a binding Head of Terms agreement with Searchlight, a rapidly-growing Canadian Women’s Health company, for an exclusive license to commercialize Estelle® in Canada. Estelle® is Mithra’s novel combined oral contraceptive (COC) product candidate currently in pivotal Phase III trials in Europe and Russia as well as in the US and Canada, with top line results expected in Q3 2018 and Q1 2019, respectively.